SGLT2 inhibitors improve heart failure through several overlapping mechanisms: they reduce fluid overload without depleting blood volume, shift the heart’s fuel source toward more efficient energy, lower inflammation and scarring in heart tissue, and protect kidney function. Originally developed to lower blood sugar in type 2 diabetes, these drugs have proven so effective in heart failure that they’re now used in patients with and without diabetes.
A Smarter Way to Remove Excess Fluid
Heart failure causes fluid to build up in your body, particularly in the tissues around your lungs, legs, and abdomen. Traditional diuretics (like furosemide) force the kidneys to flush out sodium and water, which works but comes with a cost: they pull fluid from your bloodstream, which can drop blood pressure, stress the kidneys, and trigger the body’s alarm systems to retain even more fluid.
SGLT2 inhibitors take a different approach. They block a protein in the kidneys called SGLT2 that normally reabsorbs glucose back into the blood. When that protein is blocked, glucose spills into the urine and pulls water along with it through osmotic diuresis. The key difference is what happens next. The rise in blood sodium concentration from this type of fluid loss triggers the release of vasopressin, a hormone that tells your body to drink more and your kidneys to hold onto water. This compensatory response keeps your blood volume stable while still clearing excess fluid from the tissues between your cells, the interstitial space where congestion causes the swelling and breathlessness of heart failure.
In animal studies comparing the two approaches directly, loop diuretics reduced total body water and raised markers of kidney stress after a week, while SGLT2 inhibitors maintained fluid balance and preserved kidney function over the same period. This preferential removal of interstitial fluid over blood volume is a major reason SGLT2 inhibitors don’t cause the same degree of dizziness, fatigue, or kidney deterioration that high-dose traditional diuretics can.
Shifting the Heart’s Fuel Source
Your heart burns enormous amounts of energy. Under normal conditions, it gets 60% to 90% of its fuel from fatty acids, 10% to 30% from glucose, and about 5% from ketone bodies. In heart failure, the heart is energy-starved and struggling to keep up with demand.
SGLT2 inhibitors nudge the body into a metabolic state that resembles a mild fasting response. By lowering blood glucose and improving insulin sensitivity, they shift the balance between insulin and glucagon. Glucagon rises, which mobilizes fat from storage and sends it to the liver. The liver converts those fatty acids into ketone bodies, particularly one called beta-hydroxybutyrate. With long-term SGLT2 inhibitor use, circulating ketone levels roughly double, with beta-hydroxybutyrate increasing by a median of 78% from baseline.
Why does this matter for the heart? Ketone bodies are a remarkably efficient fuel. They produce more energy per unit of oxygen consumed than glucose does. A failing heart that can tap into a richer ketone supply gets more work done with less oxygen, improving its overall efficiency. The heart even upregulates the enzymes it needs to burn ketones more effectively, suggesting it actively adapts to use this fuel source when it becomes available.
Reducing Inflammation and Scar Tissue
Heart failure isn’t just a plumbing problem. Chronic inflammation drives much of the progressive damage to heart muscle, and fibrosis (the buildup of stiff scar tissue) gradually makes the heart walls rigid and less able to pump or relax properly.
SGLT2 inhibitors directly tamp down a key inflammatory pathway called the NLRP3 inflammasome. This protein complex acts as an alarm system inside cells, and when it’s chronically activated, it drives a cycle of inflammation and tissue damage. Studies in both mouse hearts and human heart cells show that SGLT2 inhibitors suppress NLRP3 activation, partly by restoring normal calcium levels inside heart cells. They also reduce the activity of several other inflammatory signaling cascades, including NF-κB and TLR4 pathways.
On the fibrosis side, these drugs reduce collagen production in heart tissue. Experiments on human cardiac fibroblasts found that SGLT2 inhibitors pushed activated, scar-producing cells back toward a quieter, resting state. In animal models of heart failure, treated animals had lower levels of collagen types 1 and 3 and reduced expression of the enzymes that remodel the structural matrix of the heart. Less fibrosis means a more flexible heart wall, which translates to better filling and pumping.
Lowering the Heart’s Workload
SGLT2 inhibitors reduce blood pressure, which directly lowers the resistance your heart has to pump against (afterload). This improves the coupling between the heart and the blood vessels, meaning the heart can eject blood more efficiently with less wasted energy.
These drugs also appear to calm the sympathetic nervous system, the “fight or flight” wiring that’s chronically overactive in heart failure. This overactivation forces the heart to beat harder and faster than it needs to, accelerating damage over time. SGLT2 inhibitors reduce sympathetic nerve activity particularly in the kidneys, which helps explain both the blood pressure reduction and the broader cardiovascular protection.
At the cellular level, SGLT2 inhibitors block the sodium-hydrogen exchanger in heart cells. This exchanger, when overactive in heart failure, allows too much sodium and calcium to accumulate inside the cell. Excess calcium stiffens the muscle, impairs relaxation, and can trigger dangerous heart rhythms. By reducing intracellular sodium, SGLT2 inhibitors help restore healthier calcium handling, which improves both contraction and relaxation of the heart muscle.
Protecting Kidney Function
Heart failure and kidney disease feed each other in a vicious cycle. Poor heart output starves the kidneys of blood flow, and damaged kidneys retain fluid that worsens heart failure. SGLT2 inhibitors interrupt this cycle at the kidney level.
When you first start an SGLT2 inhibitor, your estimated kidney filtration rate (eGFR) typically dips slightly. This initial drop alarmed early researchers, but large clinical trials including EMPA-REG, VERTIS-CV, and CREDENCE have confirmed that this “eGFR dip” is reversible and not associated with long-term kidney damage. It actually reflects a protective recalibration: by changing how sodium is handled in the kidney tubules, SGLT2 inhibitors reduce the pressure inside the kidney’s filtering units, shielding them from the hyperfiltration damage that accelerates kidney decline.
Beyond this pressure reduction, SGLT2 inhibitors lower uric acid levels and stimulate the production of erythropoietin, a hormone that drives red blood cell production. More red blood cells means better oxygen delivery to the heart and other tissues, which is particularly valuable in heart failure where oxygen supply is already compromised.
Who Can Use Them
SGLT2 inhibitors are now recommended for heart failure regardless of whether you have diabetes. They work across both types of heart failure: reduced ejection fraction (where the heart pumps weakly) and preserved ejection fraction (where the heart is stiff and doesn’t fill properly). Most patients with kidney function above an eGFR of 20 can start these medications, though they haven’t been validated in end-stage kidney disease (eGFR below 15), in patients on dialysis, or in kidney transplant recipients.
The most common side effect is genital yeast infections, which occur 3 to 5 times more often than with placebo due to the glucose-rich urine these drugs produce. Euglycemic ketoacidosis, a condition where dangerous acid levels build up in the blood despite normal blood sugar, is rare but potentially serious and occurs primarily in patients with diabetes. The overall safety profile in heart failure populations without diabetes has been reassuringly clean in large trials, which is part of why these drugs have moved so quickly from diabetes treatment to a cornerstone of heart failure therapy.